AltPep Corporation Welcomes Dr. Alan Colowick to Board of Directors
AltPep Corporation, a privately held biotechnology company dedicated to developing early disease-modifying treatments and detection tools for amyloid diseases, has announced the appointment of Alan Colowick, M.D., M.P.H., to its Board of Directors. Dr. Colowick, a prominent leader in biotechnology investment and operations, currently serves as Senior Managing Director on the Technology-Life Sciences team at Matrix Capital Management Company, LP, and its affiliate, AyurMaya Capital Management Company, LP. His extensive background in therapeutics development and strategic leadership is expected to provide significant contributions as AltPep advances its groundbreaking research and clinical programs.
Alan Colowick’s Perspective on Joining AltPep
Expressing his enthusiasm for joining the Board, Dr. Colowick stated, “I am excited to join the AltPep Board at this pivotal point for the company. Its groundbreaking technology, aimed at targeting the early molecular triggers of amyloid diseases, truly sets AltPep apart from others in the field. I look forward to supporting AltPep’s efforts in advancing its unique and promising pipeline. Positively affecting both disease treatment and detection has the potential to help countless patients suffering from amyloid diseases.”
With a career spanning decades in biotech investment and executive leadership, Dr. Colowick brings a wealth of experience that aligns with AltPep’s mission to revolutionize the treatment and diagnosis of amyloid diseases such as Alzheimer’s and Parkinson’s.
AltPep’s Strategic Vision and Growth
Valerie Daggett, Ph.D., CEO and Founder of AltPep, expressed her excitement about Dr. Colowick’s appointment, stating, “We are pleased to welcome Alan Colowick to the AltPep Board. Alan’s deep experience as an investor, board member, and therapeutics industry leader will be invaluable as we position the company for our next phase of growth. His expertise will be particularly important as we advance our SOBIN therapeutics into Phase 1 clinical trials for Alzheimer’s and Parkinson’s diseases.”
The company is undergoing a crucial phase in its development, with a sharp focus on leveraging its innovative SOBIN therapeutics and SOBA diagnostics. Dr. Colowick’s leadership experience in guiding biotech firms through critical clinical and commercial milestones will be instrumental in driving AltPep’s long-term success.
Dr. Alan Colowick’s Background and Expertise
Dr. Colowick has an impressive track record in biotech and venture capital. Before joining Matrix Capital, he was a Partner at Sofinnova Investments, where he chaired the Board of two companies that later underwent highly successful acquisitions—Velos Bio was acquired by Merck for $2.75 billion, and Principia Biopharma was acquired by Sanofi for $3.7 billion.
Earlier in his career, Dr. Colowick held significant executive roles, including serving as CEO of Gloucester Pharmaceuticals, where he spearheaded its acquisition by Celgene. At Celgene, he went on to serve as President of EMEA, leading the company’s expansion in key global markets. Additionally, he held leadership positions at Amgen, where he contributed to the development and commercialization of groundbreaking therapies.
Dr. Colowick’s current board memberships include Acelyrin Inc., Alumis Therapeutics, Solve Therapeutics, Personalis, Inc., AC Immune SA, Harpoon Therapeutics, Inc., InCarda Therapeutics, Inc., XyloCor Therapeutics, and Teon Therapeutics, Inc. His extensive background in hematology, oncology, and strategic business growth uniquely positions him to support AltPep’s mission.
Dr. Colowick earned his M.D. from Stanford University and completed his fellowship in Hematology and Oncology at the Dana-Farber Cancer Institute. He also holds an M.P.H. from Harvard University.
Innovative SOBIN Therapeutics and SOBA Diagnostics
AltPep is pioneering the development of cutting-edge therapeutics and diagnostic tools aimed at tackling amyloid diseases at their earliest stages. Its SOBIN therapeutics are being designed for use alongside early detection, with the goal of neutralizing the toxic soluble oligomers associated with amyloid diseases. These molecules play a critical role in the progression of conditions such as Alzheimer’s and Parkinson’s disease.
In parallel, the company is advancing its SOBA diagnostics, highly sensitive blood tests intended to facilitate early and accurate diagnosis of amyloid diseases. Early detection is crucial in managing these conditions, as it enables timely intervention and improves patient outcomes. The ability to combine precise diagnostics with targeted therapeutics places AltPep in a unique position within the biotech industry.
AltPep’s Continued Progress
With the addition of Dr. Colowick to its Board of Directors, AltPep is reinforcing its commitment to driving innovation in the biotechnology sector. His experience navigating complex clinical and commercial landscapes will play a crucial role as the company advances its research and prepares to enter Phase 1 clinical trials.
AltPep’s focus remains steadfast on transforming the future of amyloid disease treatment through its pioneering approach. By leveraging cutting-edge scientific discoveries and a world-class leadership team, the company is well-positioned to make a lasting impact in the field of neurodegenerative disease research and treatment.
As AltPep continues to grow and achieve key milestones, stakeholders and industry watchers will be keenly observing its progress. The appointment of Dr. Alan Colowick is a testament to the company’s commitment to excellence, and his expertise will be instrumental in shaping AltPep’s path forward.
